MedTrace Logo

To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions

NCT00883064 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-03-29

No results posted yet for this study

Summary

To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions.

Conditions

Interventions

DRUG

Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)

DRUG

Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)

Sponsors & Collaborators

Principal Investigators

  • Eric Masson, Pharm.D. · Anapharm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-03-31
Primary Completion
2000-04-30
Completion
2000-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00883064 on ClinicalTrials.gov